WAIKOLOA, Hawaii — Progress in cell and gene therapies for the treatment of wet and dry age-related macular degeneration is evidenced by advancement, albeit slow, of clinical trials, according to a speaker here.Janssen and Ocata are both initiating phase 2 trials of cell therapy for atrophic AMD, and a phase 2 study of NeuroTech’s implant platform that combines cell and gene therapy for treatment of wet AMD is ongoing, Allen C. Ho, MD, told colleagues at Retina 2016.
WAIKOLOA, Hawaii — Developments in widefield imaging continue to progress at a rapid pace and the technology may have a place in detecting and staging diabetic retinopathy, according to a speaker here.Historically, diabetic retinopathy severity has been staged based on ETDRS seven standard fields; however, recent pilot studies that looked beyond those fields using ultra-widefield imaging found patients with peripheral lesions were at increased risk for progression to proliferative diabetic retinopathy, SriniVas R. Sadda, MD, told colleagues at Retina 2016.
WAIKOLOA, Hawaii — David F. Chang, MD, who moderated Tuesday’s interactive Cataract Surgery Complications: You Make the Call program, was named Speaker of the Day for the Comprehensive Ophthalmology Program. Roger F. Steinert, MD, who co-moderated with Chang another section on Tuesday, Current Controversies: Endophthalmitis Prophylaxis, shared with the audience Chang’s year-long commitment to putting together much of Monday’s and Tuesday’s programming. Chang is clinical professor, University of California, San Francisco.
WAIKOLOA, Hawaii — Patients who are treated with ranibizumab for neovascular AMD may be at risk for developing macular atrophy, according to a speaker here.“Is [macular atrophy] truly associated with VEGF inhibition or is this the natural disease progression? Other conditions in which we treat VEGF inhibition aggressively such as diabetic macular edema or retinal vein occlusion do not develop the macular atrophy we see in neovascular AMD,” Diana V. Do, MD, said here at Retina 2016.
WAIKOLOA, Hawaii — At Hawaiian Eye, Jodi Luchs, MD, discusses a simple in-office test for ocular allergy that tests for 60 different antigens.
WAIKOLOA, Hawaii — At Hawaiian Eye, Jack T. Holladay, MD, MSEE, discusses how to achieve 0.5 D of residual astigmatism in cataract surgery, which is agreed upon as the highest amount of residual astigmatism allowable to have patients who are happy with their visual outcome.